Literature DB >> 1551529

Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.

S Ramel1, B J Reid, C A Sanchez, P L Blount, D S Levine, K Neshat, R C Haggitt, P J Dean, K Thor, P S Rabinovitch.   

Abstract

Barrett's esophagus is a condition in which the normal stratified squamous epithelium is replaced by metaplastic columnar epithelium that predisposes to the development of esophageal adenocarcinoma. Neoplastic progression in Barrett's esophagus occurs by a multistep process associated with genomic instability and the development of aneuploid cell populations. p53 protein overexpression and allelic deletions on chromosome 17p have been shown to be present in some Barrett's adenocarcinomas, but the stage in neoplastic progression at which p53 protein overexpression develops has not been investigated. To determine the stages in neoplastic progression at which p53 protein overexpression could be detected, biopsy specimens from patients with Barrett's esophagus at all stages of histological progression from Barrett's metaplasia negative for dysplasia to esophageal adenocarcinoma were investigated using a multiparameter flow-cytometric assay. p53 protein overexpression was found in 1 of 21 patients (5%) with Barrett's metaplasia negative for dysplasia, 2 of 13 patients (15%) with Barrett's metaplasia with abnormalities in the indefinite/low-grade dysplasia range, 5 of 11 patients (45%) with high-grade dysplasia, and 8 of 15 patients (53%) with Barrett's adenocarcinoma (P less than 0.01). p53 protein overexpression was found in 9% of patients with Barrett's esophagus who had neither high-grade dysplasia nor adenocarcinoma. Whether or not patients whose biopsy specimens show p53 protein overexpression are at increased risk for progression to adenocarcinoma can be determined by prospective endoscopic surveillance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551529

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  31 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Parathyroid hormone-related protein production by adenocarcinoma in Barrett's esophagus patient with dermatomyositis.

Authors:  S Tanabe; H Mitomi; M Sada; I Yamazaki; T Akaboshi; I Okayasu; T Kameya; K Saigenji
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

Review 3.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

4.  Risk factors associated with Barrett's epithelial dysplasia.

Authors:  Mikiko Fujita; Yuri Nakamura; Saeko Kasashima; Maiko Furukawa; Ryoichi Misaka; Hikaru Nagahara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  Foveolar hyperplasia following partial gastrectomy results from expansion of surface mucous cell compartment.

Authors:  G S Ray; M W Jackson; J R Goldenring
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

6.  Biochemical analysis of the stress protein response in human oesophageal epithelium.

Authors:  D Hopwood; S Moitra; B Vojtesek; D A Johnston; J F Dillon; T R Hupp
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

7.  Impact of tumor progression on cancer incidence curves.

Authors:  E Georg Luebeck; Kit Curtius; Jihyoun Jeon; William D Hazelton
Journal:  Cancer Res       Date:  2012-10-10       Impact factor: 12.701

Review 8.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

9.  Overexpression of p53 protein in Barrett's syndrome with malignant transformation.

Authors:  J F Fléjou; F Potet; F Muzeau; F Le Pelletier; F Fékété; D Hénin
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

Review 10.  Barrett's esophagus: model of neoplastic progression.

Authors:  Stig Ramel
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.